Prevention of post ERCP pancreatitis: An overview

Annals of Gastroenterology

Volumn 21, Issue 1, 2008, Pages 27-38

  Lazaraki, Georgia ^a   Katsinelos, P ^a,b  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CORTICOSTEROID; DICLOFENAC; GABEXATE MESILATE; GLYCERYL TRINITRATE; HEPARIN; HYDROCORTISONE; LIDOCAINE; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; NIFEDIPINE; OCTREOTIDE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 10; SOMATOSTATIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ABDOMINAL PAIN; ANATOMICAL VARIATION; BILIARY TRACT DISEASE; BLEEDING; CANNULATION; CLINICAL TRIAL; CONTINUOUS INFUSION; DEATH; DISABILITY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HYPERAMYLASEMIA; LOADING DRUG DOSE; MULTIPLE ORGAN FAILURE; NONHUMAN; ODDI SPHINCTER; PANCREAS DISEASE; PANCREAS NECROSIS; PANCREAS SECRETION; PANCREATITIS; PATIENT SELECTION; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SKILL; STENT;

EID: 48249153463     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Cheng CL, Sherman S, Watkins JL, et at. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101:139-47.
2. Hookey LC, RioTinto R, Delhaye M, Baize M, Le Moine O, Deviere J. Risk factors for pancreatitis after pancreatic sphincterotomy: a review of 572 cases. Endoscopy 2006; 38:670-76.
3. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc; 2001; 54:425-34.
4. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotorny. N Engl J Med 1996; 335:909-18.
5. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariani A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med 1996; 335:919-23
6. Christoforidis E, Goulimaris I, Kanellos I, Tsalis K, Demetriades C, Betsis D. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy 2002;34:286-92.
7. Masci E, Mariani A, Curioni S, Testoni P. Risk Factors for pancreatitis following endoscopic retrograde cholangiopancreatography: A Meta-Analysis. Endoscopy 2003; 35: 830-34.
8. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10.
9. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417-23.
10. Conn M, Goldenberger A, Concepcion L, Mandeli J. The effect of ERCP on circulating pancreatic enzymes and pancreatic protease inhibitors. Am J Gastroenterol 199 1; 86: 1011-14.
11. Sternlieb J, Aronchick C, Retig J, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992: 11: 1561-6.
12. Bhatia V, Garg PK, Tandon RK, Madan K. Endoscopic retrograde cholangiopancreatography-induced acute pancreatitis often has a benign outcome. J Clin Gastroenterol 2006;40:726-31.
13. Bradley EL. A clinically-based classification system for acute pancreatitis. Arch Surg 1993; 128:586-90.
14. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus, Gastrointest Endosc 1991; 37:383-93.
15. Thomas PR, Sengupta S. Prediction of pancreatitis following endoscopic retrograde cholangiopancreatography by the 4-h post procedure amylase level. J Gastroenterol Hepatol 2001; 16:923-26.
16. Oezeueruemez-Porsch M, Kunz D, Hardt PD, et al. Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitoninin early phase of post-ERCP pancreatitis. Dig Dis Sci 1998; 43:1763-69.
17. Kaw M, Singh S. Serum lipase, C-reactive protein, and interleukin-6 levels in ERCP-induced pancreatitis. Gastrointest Endosc 2001; 54:435-40.
18. Messman H, Vogt W, Holstege A, et al. Post-ERCP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997;40;80-85.
19. Saari A, Kivisaari L, Standertskjold-Nordenstam CG, Brackett K, Schroder T. Experimental pancreatography: a comparison of three contrast media. Scand J Gastroenterol 1988; 23:53-8.
20. Akashi R, Kiyozumi T, Tanaka T, Sakurai K, Oda Y, Sagara K. Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc 2002; 55:50-4.
21. Tulassay Z, Papp J, Koranyi L, Szathmari M, Tamas G Jr. Hormonal and biochemical changes following endoscopic retrograde cholangio-pancreatography. Acta Gastroenterol Belg 1981; 44:538-44.
22. Skude G, Wehlin L, Maruyama T, Ariyama J. Hyperamylasaemia after duodenoscopy and retrograde cholangiopancreatography. Gut 1976; 17:127-32.
23. Okuno M, Himeno S, Kurokawa M, et al. Changes in serum levels of pancreatic isoamylase, lipase, trypsin, and elastase 1 after endoscopic retrograde pancreatography. Hepatogastroenterology 1985; 32:87-90.
24. Kasugai T, Kuno N, Kizu M. Manometric endoscopic retrograde pancreatocholangiography. Technique, significance, and evaluation. Am J Dig Dis 1974; 19:485-502.
25. Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials Gastrointest Endosc 2004; 60:544-50.
26. Fogel EL, Eversman D, Jamidar P, Sherman S, Lehman GA. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy 2002;34:280-5.
27. Tarnasky PR, Palesch YY, Cunningham JT, Mauldin PD, Cotton PB, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998;115:1518-24.
28. Fazel A, Quadri A, Catalano MF, Meyerson SM, Geenen JE. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 2003; 57:291-94.
29. Sherman S, Earle DT, Bucksot L, Baute P, Gottlieb K, Lehman G. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy (ES)-induced pancrcatitis? A final analysis of a randomized prospective study. [abstract]. Gastrointest Endosc 1996; 43: A489
30. Smithline A, Silverman W, Rogers D, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993;39:652-7.
31. Sherman S et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy induced pancreatitis? Am J Gastroenterol 1995;90: 1614
32. Singh P, Sivak MV, Agarwal D. et al. Prophylactic pancreatic stenting for prevention of post-ERCP acute pancreatitis: a meta-analysis of controlled trials [abstract]. Gastrointest Endosc 2003; 57: AB 89.
33. Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56:652-56.
34. Rabenstein T, Schneider HT, Bulling D, et al. Analysis of the risk factors associated with endoscopic sphincterotomy techniques: preliminary results of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment. Endoscopy 2000;32:10-9.
35. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002;56:488-95.
36. Guelrud M, Mendoza S, Rossiter G, Ramirez L, Barkin J. Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia. Gastroenterology 1988;95:1050-5.
37. Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002;56:202-8.
38. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993;54:105-11.
39. Wehrmann T, Schmitt T, Stergiuo N, et al.. Topical application of nitrates onto the papilla of Vater: manometric and clinical results. Endoscopy 2001;33:323-28.
40. Schwartz JJ, Lew RJ, Ahmad NA, et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004;59:179-84.
41. Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001;88:1178-82.
42. Moreto M, Zaballa M, Casado I, et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: a randomized double-blind trial. Gastrointest Endosc 2003;57:1-7.
43. Kaffes AJ, Bourke MJ, Ding S, Alrubaie A, Kwan V, Williams SJ. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis. Gastrointest Endosc 2006;64:351-57.
44. Muralidharan V, Jamidar P. Pharmacologic prevention of post-ERCP pancreatitis: is nitroglycerin a sangreal? Gastrointest Endosc 2006;64:358-60.
45. Raty S, Sand J, Pulkkinen M, Matikainen M, Nordback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001;5:339-45
46. Niederau C, Pohlmann U, Lubke H, Thomas L. Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: results of a randomized controlled clinical study. Gastrointest Endosc 1994;40:533-37.
47. Weiner GF, Geenen JE, Hogan WJ, Catalano MF. Use of corticosteroids in the prevention of post-ERCP pancreatitis. Gastrointest Endose 1995;42:579-83.
48. Budzynska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001;33:766-72.
49. De Palma GD, Catanzano C. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999;94:982-85.
50. Dumot JA, Conwell DL, O'Connor JB, et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 1998;93:61-5
51. Sherman S, Blaut U, Watkins JL, et al. Does prophylactic steroid administration reduce the risk and severity of post-ERCP pancreatitis: a randomized prospective multicenter study. Gastrointest Endosc 2003;58:23-9.
52. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002;55:470-75.
53. Testoni PA, Mariani A, Masci E, Curioni S. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. Dig Liver Dis 2006;38:588-95.
54. Mosler P, Sherman S, Marks J, et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc 2005;62:245-50.
55. Katsinelos P, Kountouras J, Chatzis J, et al. High-dose allopurinol for prevention of PEP: a prospective randomized double-blind controlled trial. Gastrointest Endosc 2005;61:407-15.
56. Harewood GC, Topazian M. Post-ERCP pancreatitis: is allopurinol the Holy Grail? Gastrointest Endosc 2005;62:251-52.
57. Katsinelos P, Kountouras J, Paroutoglou G, Beltsis A, Mimidis K, Zavos C. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 2005;62:105-11.
58. Sherman S, Lehman G, Geenen JE, et al. Evaluation of recombinant human platelet activating factor acetylhydolase (RPAF-AH) for reducing the incidence and severity of post-ERCP acute pancreatitis. [abstract]. Gastrointest Endosc 2000;51:AB67
59. Rongione AJ, Kusske AM, Kwan Y, Ashley SW, Reber HA, McFadden DW. Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology 1997;112:960-67
60. Van Laethem JL, Marchant A, Delvaux A, et al. Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology 1995;108: 1917-22.
61. Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113:383-89.
62. Singh P, Lee T, Davidoff S, Bank S. Efficacy of Interleukin 10 (IL10) in the prevention of post-ERCP pancreatitis: a meta-analysis. [abstract]. Gastrointest Endosc 2002;55: AB150.
63. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003;124:1786-91
64. Masci E, Cavallini G, Mariani A, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003;98:2182-6.
65. Testoni PA, Cicardi M, Bergamaschini L, et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 1995; 42:301-5.
66. Ruud TE, Aasen AO, Pillgram-Larsen J, Stadaas JO. Effects on peritoneal proteolysis and haemodynamics of prophylactic infusion with C1 inhibitor in experimental acute pancreatitis. Scand J Gastroenterol 1986; 21:1018-24.
67. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000;51:1-7.
68. Testoni PA, Mariani A, Masci E, Curioni S. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. Dig Liver Dis 2006;38:588-95.
69. Andriulli A, Solmi L, Loperfido S, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004;2:713-8.
70. Zheng M, Chen Y, Yang X, Li J, Zhang Y, Zeng Q. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2007 Feb 12;7:6.
71. Salas A, Sans M, Soriano A, et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88-96.
72. Rabenstein T, Schneider HT, Nicklas M, et al. Impact of skill and experience of the endoscopist on the outcome of endoscopic sphincterotomy techniques. Gastrointest Endosc 1999; 50:628-36.
73. Rabenstein T, Schneider HT, Bulling D, et al. Analysis of risk factors of endoscopic sphincterotomy techniques: preliminary results of a prospective study with emphasis on the reduced risk of acute pancreatitis under low-dose anticoagulation. Endoscopy 2000;32:10-9.
74. Hackert T, Werner J, Gebhard MM, Herfarth C, Klar E. Prevention of post-ERCP pancreatitis by heparin in rats. [abstract]. Gastroenterology 2000;118:A42
75. Rabenstein T, Fischer B, Wiessner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004;59:606-13.
76. Karalis K, Mastorakos G, Chrousos GP, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93:2000-6.
77. Baxter JN, Jenkins SA, Day DW, et al. Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br J Surg 1985; 72:382-5.
78. Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL, Fan ST. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999;49:593-98.
79. Poon RT, Yeung C, Liu CL, et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut. 2003;52:1768-73.
80. Andriulli A, Caruso N, Quitadamo M, et al. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a metaanalysis study. JOP 2003;4:41-8.
81. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 2004;19:278-82.
82. Arvanitidis D, Hatzipanayiotis J, Koutsounopoulos G, Frangou E. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP. Hepatogastroenterology 1998;45:248-52.
83. Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992;87:1561-6.
84. Binmoeller KF, Dumas R, Harris AG, Delmont JP. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992;37:773-7.
85. Lung E. The use of somatostatin or octreotide to prevent post-ERCP pancreatitis: a meta-analysis of randomized, controlled trials. [abstract] Gastrointest Endosc 2004;59:. AB107
86. Thomopoulos K, Pagoni N, Vagenas K,et al. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post ERCP pancreatitis. Gastrointest Endosc 2006;64:Number 5.
87. Gullo L, Pezzilli R, Ancona D. Effect of octreotide, a long-acting somatostatin analogue, on plasma amino acid uptake by the pancreas. Pancreas 1991;6:668-72.
88. Malfertheiner P, Mayer D, Buechler M. Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide. Gut 1995;36:450-54.
89. Testoni PA, Bagnolo F, Andriulli A. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001;15:965-72.
90. Akashi R, Kiyozumi T, Tanaka T, Sakurai K, Oda Y, Sagara K. Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc 2002; 55:50-4.
91. Mairose UB, Wurbs D, Classen M. Santorini's duct - an insignificant variant from normal or an important overflow valve? Endoscopy 1978; 10:24-9.
92. Elton E, Howell DA, Parsons WG, Qaseem T, Hanson BL. Endoscopic pancreatic sphincterotomy: indications, outcome, and a safe stentless technique. Gastrointest Endosc 1998;47:240-9.
93. Patel R, Tarnasky P, Hennessy WS, Hawes R, Payne KM, Nelles SE, et al. Does stenting after pancreatic sphincterotomy reduce post-ERCP pancreatitis in patients with prior biliary sphincterotomy? Preliminary results of a prospective randomized trial. [abstract]. Gastrointest Endosc 1999;49: AB80
94. Norton ID, Gostout CJ, Baron TH, Geller A, Petersen BT, Wiersema MJ. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 2002;56:239-43.
95. Desilets DJ, Dy RM, Ku PM, et al. Endoscopic management of tumors of the major duodenal papilla: refined techniques to improve outcome and avoid complications. Gastrointest Endosc 2001;54:202-8.
96. Catalano MF, Linder JD, Chak A, et al. Endoscopic management of adenoma of the major duodenal papilla. Gastrointest Endosc 2004;59:225-32.
97. Aizawa T, Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc 2001;54:209-13.
98. Freeman ML, Overby C, Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc 2004;5:8-14.
99. Vandervoort J, Soetikno RM, Montes H, et al. Accuracy and complication rate of brush cytology from bile duct versus pancreatic duct. Gastrointest Endosc 1999;49:322-7.
100. Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60:544-50.
101. Brackbill S, Young S, Schoenfeld P, Elta G. A survey of physician practices on prophylactic pancreatic stents. Gastrointest Endosc 2006;64:45-52.
102. Rashdan A, Fogel E, McHenry L, Sherman S, Schmidt S, Lazzell L, et al. Pancreatic ductal changes following small diameter long length unflanged pancreatic stent placement. [abstract]. Gastrointest Endosc 2003;57:AB213.
103. Rashdan A, Fogel EL, McHenry L Jr, Sherman S, Temkit M, Lehman GA. Improved stent characteristics for prophylaxis of post-ERCP pancreatitis. Clin Gastroenterol Hepatol 2004;2:322-329.
104. Das A, Singh P, Sivak MV Jr, Chak A. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis. Gastrointest Endosc 2007; 65:960-968
105. Lella F, Bagnolo F, Colombo E, Bonassi U. A simple way of avoiding post-ERCP pancreatitis. Gastrointest Endosc 2004;59:830-4.
106. Michopoulos S, Stamatis G, Manthos G, et al. Randomized trial comparing the tip of the hydrophilic guide wire for successful deep cannulation of the common bile duct. Gastrointest Endosc 2005;65: AB213
107. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004;59:845-64.
108. Classen M. Endoscopic papillotomy. In: Sivak MV, ed. Gastroenterologic Endoscopy. Philadelphia: WB Saunders, 1987:631-651.